Ken Griffin Denali Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $23,056 - $34,155	-1,100 Reduced 7.1%	14,400 $419,000
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $52,360 - $81,270	-3,500 Reduced 18.42%	15,500 $359,000
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $196,292 - $289,540	12,400 Added 187.88%	19,000 $389,000
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $64,800 - $92,720	-4,000 Reduced 37.74%	6,600 $141,000
Q3 2023 Nov 14, 2023	SELL	$20.63 - $30.17 $2,063 - $3,017	-100 Reduced 0.93%	10,600 $218,000
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $273,429 - $385,632	-11,700 Reduced 52.23%	10,700 $315,000
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $70,112 - $104,544	-3,200 Reduced 12.5%	22,400 $516,000
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $281,196 - $362,944	10,700 Added 71.81%	25,600 $711,000
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $114,268 - $169,532	-4,400 Reduced 22.8%	14,900 $457,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.